Dr. Mark Pegram & Dr. Neil Iyengar - Beyond CLEOPATRA: T-DXd’s Rise in HER2+ and HER2-Low Breast Cancer

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/a8/e9/5f/a8e95f8b-aa1d-fc10-a97d-970ed536395a/mza_6256469873985417328.jpg/600x600bb.jpg

Community Health Media

8 episodes

3 days ago

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts

Medicine

Health & Fitness

RSS

All content for Community Health Media is the property of Community Health Media and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/42498441/42498441-1762780613924-2c9b2e94eadf8.jpg

Dr. Mark Pegram & Dr. Neil Iyengar - Beyond CLEOPATRA: T-DXd’s Rise in HER2+ and HER2-Low Breast Cancer

Community Health Media

31 minutes 45 seconds

4 days ago

Dr. Mark Pegram & Dr. Neil Iyengar - Beyond CLEOPATRA: T-DXd’s Rise in HER2+ and HER2-Low Breast Cancer

Direct from ESMO 2025 in Berlin, Dr. Mark Pegram and Dr. Neil Iyengar unpack what many are calling a new standard in HER2-directed therapy.

From DESTINY-Breast 11’s practice-changing neoadjuvant results to DESTINY-Breast 05 in the adjuvant setting — and now DESTINY-Breast 09 rewriting the metastatic playbook — the data are clear: trastuzumab deruxtecan (T-DXd) is transforming treatment across disease stages.

The discussion moves beyond HER2 + disease into HER2-low and ultra-low, touching on how new definitions, ADC sequencing, and precision testing could expand eligibility to the majority of breast cancers.

🎧 Tune in for a high-impact, expert-level recap of the trials defining the next chapter of HER2 oncology.

#BreastCancer #ESMO2025 #OncologyPodcast #HER2Positive #HER2Low #TDXd #Pegram #Iyengar #TrastuzumabDeruxtecan #CancerResearch #BreastOncology #PrecisionOncology #CHM

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media